Novel low-glucose degradation products (GDP) peritoneal dialysis (PD) fluids have an improved biocompatibility profile as compared to standard fluids. Clinical studies suggest that their use may be associated with favorable clinical outcomes; however, large prospective randomized studies addressing clinical endpoints such as patient and technique survival are presently lacking. Nevertheless, as their only disadvantage is their cost, they are already being used as the standard treatment by many adult PD centers. This policy is also in line with the latest recommendations from the European Pediatric Dialysis Working Group which advises that conventional, single-chamber PD solutions should be replaced by PD solutions with reduced GDP content. The use of icodextrin, the glucose polymer PD solution, is recommended for patients with high or high-average peritoneal transport and/or ultrafiltration problems who otherwise would resort to hypertonic (3.86% glucose) exchanges.

1.
Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470–479.
2.
Witowski J, Ksiazek K, Jörres A: New insights into the biology of peritoneal mesothelial cells: the roles of epithelial-to-mesenchymal transition and cellular senescence. Nephron Exp Nephrol 2008;108:e69–e73.
3.
Witowski J, Jörres A: Peritoneal Dialysis: A Biological Membrane with a Nonbiological Fluid. Contrib Nephrol. Basel, Karger, 2009, vol 163, pp 27–34.
4.
Witowski J, Ksiazek K, Jörres A: Glucose-induced mesothelial cell senescence and peritoneal neoangiogenesis and fibrosis. Perit Dial Int 2008;28(suppl 5):S34–S37.
5.
Jörres A, Gahl GM, Frei U: Peritoneal dialysis fluid biocompatibility: does it really matter? Kidney Int Suppl 1994;48:S79–S86.
6.
Jörres A: Effect of peritoneal dialysis on peritoneal cell biology: peritoneal fibroblasts. Perit Dial Int 1999;19(suppl 2):S348–S352.
7.
Nilsson Thorell CB, Muscalu N, Andren AH, Kjellstrand PT, Wieslander AP: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1993;13:208–213.
8.
Lamb EJ, Cattell WR, Dawnay AB: In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995;47:1768–1774.
9.
Witowski J, Jörres A: Glucose degradation products: relationship with cell damage. Perit Dial Int 2000;20(suppl 2):S31–S36.
10.
Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jörres A: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12:2434–2441.
11.
Jörres A: Glucose degradation products in peritoneal dialysis: from bench to bedside. Kidney Blood Press Res 2003;26:113–117.
12.
Witowski J, Bender TO, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A, Jörres A: Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int 2003;23:381–390.
13.
Topley N, Kaur D, Petersen MM, Jörres A, Williams JD, Faict D, Holmes CJ: In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996;7:218–224.
14.
Topley N, Kaur D, Petersen MM, Jörres A, Passlick Deetjen J, Coles GA, Williams JD: Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 1996;49:1447–1456.
15.
Jörres A, Bender TO, Finn A, Witowski J, Fröhlich S, Gahl GM, Frei U, Keck H, Passlick-Deetjen J: Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998;54:2184–2193.
16.
Witowski J, Jörres A: Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. Perit Dial Int 2005;25(suppl 3):S31–S34.
17.
Topley N, Michael D, Bowen T: CA125: Holy Grail or a poisoned chalice. Nephron Clin Pract 2005;100:c52–c54.
18.
Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408–418.
19.
Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ: Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int 1997;17:373–378.
20.
Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, Law MC, Li PK: Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products – a 1-year randomized control trial. Nephrol Dial Transplant 2007;22:552–559.
21.
Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298–305.
22.
Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, Misselwitz J, Pieper AK, Schaefer F: Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 2007;22:2038–2044.
23.
Park SH, Do JY, Kim YH, Lee HY, Kim BS, Shin SK, Kim HC, Chang YK, Yang JO, Chung HC, Kim CD, Lee WK, Kim JY, Kim YL: Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study. Nephrol Dial Transplant 2011, E-pub ahead of print.
24.
Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Kim MJ, Shin SK: Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006;21:2893–2899.
25.
Han SH, Ahn SV, Yun JY, Tranaeus A, Han DS: Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 2009;54:711–720.
26.
Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Ahn C, Kim MJ, Shin SK: Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005;25:248–255.
27.
Ahmad S, Sehmi JS, Ahmad-Zakhi KH, Clemenger M, Levy JB, Brown EA: Impact of new dialysis solutions on peritonitis rates. Kidney Int Suppl 2006;103:S63–S66.
28.
Montenegro J, Saracho R, Gallardo I, Martinez I, Munoz R, Quintanilla N: Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 2007;22:1703–1708.
29.
Tranaeus A: A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution – clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000;20:516–523.
30.
Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM: Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008;73:200–206.
31.
Fang W, Mullan R, Shah H, Mujais S, Bargman JM, Oreopoulos DG: Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study. Perit Dial Int 2008;28:35–43.
32.
Pajek J, Kveder R, Bren A, Gucek A, Bucar M, Skoberne A, Waniewski J, Lindholm B: Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrol Dial Transplant 2009;24:1617–1625.
33.
Choi HY, Kim DK, Lee TH, Moon SJ, Han SH, Lee JE, Kim BS, Park HC, Choi KH, Ha SK, Han DS, Lee HY: The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008;28:174–182.
34.
Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, Oh KH: Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009;24:2899–2908.
35.
Haag-Weber M, Kramer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R, DIUREST Study Group: Low-GDP fluid (Gambrosol Trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010;25:2288–2296.
36.
Johnson DW, Clarke M, Wilson V, Woods F, Brown FG: Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. BMC Nephrol 2010;11:25.
37.
Garcia-Lopez E, Lindholm B: Icodextrin metabolites in peritoneal dialysis. Perit Dial Int 2009;29:370–376.
38.
Wolfson M, Piraino B, Hamburger RJ, Morton AR: A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002;40:1055–1065.
39.
Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S: Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005;16:546–554.
40.
Paniagua R, Ventura MD, Avila-Diaz M, Cisneros A, Vicente-Martinez M, Furlong MD, Garcia-Gonzalez Z, Villanueva D, Orihuela O, Prado-Uribe MD, Alcantara G, Amato D: Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 2009;29:422–432.
41.
Lin A, Qian J, Li X, Yu X, Liu W, Sun Y, Chen N, Mei C: Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. Clin J Am Soc Nephrol 2009;4:1799–1804.
42.
Wilkie ME, Plant MJ, Edwards L, Brown CB: Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997;17:84–87.
43.
Johnson DW, Arndt M, O’Shea A, Watt R, Hamilton J, Vincent K: Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001;2:2.
44.
Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, Gerlag PG, Hoorntje SJ, Wolters J, Van Der Sande FM, Leunissen KM: Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003;63:1556–1563.
45.
Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC: Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003;14:2338–2344.
46.
Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, MacNamara E, Ekstrand A, Tranaeus A, Filho JC: Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005;67:1609–1615.
47.
Bender TO, Witowski J, Ksiazek K, Jörres A: Comparison of icodextrin- and glucose-based peritoneal dialysis fluids in their acute and chronic effects on human peritoneal mesothelial cells. Int J Artif Organs 2007;30:1075–1082.
48.
Konings CJ, Schalkwijk CG, Van Der Sande FM, Leunissen KM, Kooman JP: Influence of icodextrin on plasma and dialysate levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine. Perit Dial Int 2005;25:591–595.
49.
Holmes CJ, Shockley TR: Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000;20(suppl 2):S37–S41.
50.
Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW: Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003;64:1480–1486.
51.
Van V, Schoonjans RS, Struijk DG, Verbanck JJ, Vanholder RC, Van B, Lefebvre RA, De V, Lameire NH: Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int 2002;22:32–38.
52.
Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R: Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001;21:275–281.
53.
Goldsmith D, Jayawardene S, Sabharwal N, Cooney K: Allergic reactions to the polymeric glucose-based peritoneal dialysis fluid icodextrin in patients with renal failure. Lancet 2000;355:897.
54.
Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier MA, Mendoza O, Goud N, Costigan A, Denjoy N, Verger C, Owen WF Jr: Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 2005;365:588–594.
55.
Rozenberg R, Magen E, Weissgarten J, Korzets Z: Icodextrin-induced sterile peritonitis: the Israeli experience. Perit Dial Int 2006;26:402–405.
56.
Basile C, De PF, Montanaro A, Giordano R: The impact of relapsing sterile icodextrin-associated peritonitis on peritoneal dialysis outcome. J Nephrol 2003;16:384–386.
57.
Perl J, Nessim SJ, Bargman JM: The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both? Kidney Int 2011;79:814–824.
58.
Schmitt CP, Bakkaloglu SA, Klaus G, Schroder C, Fischbach M: Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group. Pediatr Nephrol 2011;26:1137–1147.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.